Navigation Links
Ferring Pharmaceuticals' EUFLEXXA(R) to Serve as a Sponsor for the Babolat World Tennis Classic
Date:5/13/2008

PARSIPPANY, N.J., May 13 /PRNewswire/ -- Ferring Pharmaceuticals Inc. has announced that EUFLEXXA(R) (1% sodium hyaluronate), its hyaluronic acid (HA) therapy for the pain of knee osteoarthritis, will serve as a sponsor for the Babolat World Tennis Classic.

The Babolat World Tennis Classic is a Category II United States Tennis Association sanctioned tournament held in Rancho Mirage, CA for men and women aged 35-85. The largest adult tennis tournament of its kind in the world, most recently the Classic featured a record 770 matches with entrants representing 35 states and five foreign countries.

"We are excited to be part of such an amazing event," said Alex Drigan, Product Director for EUFLEXXA(R). "Tennis is a lifelong sport that helps keep people healthy and active. We strongly believe in events that offer people an opportunity to enjoy competitive athletics later in life."

Entering its 22nd year, the 2009 Babolat Tennis World Classic will be held from January 25 to February 1 at the Mission Hills Country Club in Rancho Mirage, CA.

About EUFLEXXA(R)

EUFLEXXA(R) (1% sodium hyaluronate) is the first and only non-avian derived hyaluronic acid approved in the U.S. for the treatment of pain caused by knee osteoarthritis and continues to be the fastest growing brand of HA on the market.(1) EUFLEXXA(R) is indicated for a three-injection treatment regimen for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen). In a prospective, randomized, double-blind, head-to-head study versus the market leading HA therapy, significantly more patients were "pain-free" and "symptom-free" with EUFLEXXA(R).(2)

The process used to manufacture EUFLEXXA(R) produces the HA that most closely resembles the HA in healthy human synovial fluid and the most highly purified HA product available today. In addition, since it is not derived from an avian source (chicken or rooster combs), the risk of reactions related to avian proteins is eliminated.(3-8)

EUFLEXXA(R) received PMA approval from the U.S. Food and Drug Administration (FDA) on December 3, 2004, and became available to the public on November 8, 2005. For more information, visit http://www.EUFLEXXA.com.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc., part of the Ferring Group, is a privately owned, international pharmaceutical company. Ferring's line of orthopaedic products includes EUFLEXXA(R), hyaluronic acid for pain from osteoarthritis in the knee.

Ferring also markets BRAVELLE(R) (urofollitropin for injection, purified), MENOPUR(R) (menotropins for injection, USP) and REPRONEX(R) (menotropins for injection, USP), Novarel(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN(R) (progesterone) Vaginal Insert, 100 mg in the U.S. to infertility specialists and their patients. Ferring also offers the Q-CAP(TM), the first and only needle-free reconstitution device, for use with its fertility treatments.

Other products include: ACTHREL(R) (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing's syndrome; DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis; and PROSED(R)/DS for the relief of discomfort of the lower urinary tract.

The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit http://www.FerringUSA.com.

Important Treatment Considerations

EUFLEXXA(R) (1% sodium hyaluronate) is indicated for the treatment of knee pain due to osteoarthritis (OA). It is used in people who have failed to get adequate pain relief either from simple pain medications, such as acetaminophen, or from exercise and/or physical therapy. EUFLEXXA(R) should not be used in people who have had any previous allergic reaction to hyaluronate preparations or who have knee joint infections or skin diseases in the area of the injection site. In a randomized, double-blind, multicenter clinical trial, the only adverse events reported with EUFLEXXA(R) at an incidence of 5% or greater were arthralgia (joint pain) (8.75%) and back pain (5%). Temporary knee pain and swelling may occur after injection with EUFLEXXA(R). The safety and effectiveness of injecting EUFLEXXA(R) into the knee together with other injectable medications or into joints other than the knee have not been studied. The safety and effectiveness of treatment cycles of fewer than 3 injections or of repeated treatment cycles with EUFLEXXA(R) have not been established. Strict aseptic technique must be followed to avoid joint infection.

It is recommended to avoid strenuous activity or prolonged weight-bearing activities such as jogging or tennis within 48 hours following intra-articular injection.

1 IMS National Sales Perspective Data, February 2008

2 Kirchner M, Marshall D. A double-blind randomized controlled trial

comparing alternate forms of high molecular weight hyaluronan for the

treatment of osteoarthritis of the knee. Osteoarthritis Cartilage.

2006; 14: 154-162.

3 Schiavinato A, Finesso M, Cortivo R, & Abatangelo G. Comparison of the

effects of intra-articular injections of Hyaluronan and its chemically

cross-linked derivative (Hylan G-F20) in normal rabbit knee joints. Clin

Exp Rheumatol. 2002; 20: 445-454.

4 Goomer RS, Leslie K, Maris T, & Amiel D. Native hyaluronan produces less

hypersensitivity than cross-linked hyaluronan. Clin Orthop Relat Res.

2005; 434: 239-245.

5 Leopold SS, Warme WJ, Pettis PD, & Shott S. Increased frequency of acute

local reaction to intra-articular hylan GF-20 (synvisc) in patients

receiving more than one course of treatment. J Bone Joint Surg Am. 2002;

84-A: 1619-1623.

6 Puttick MP, Wade JP, Chalmers A, Connell DG, & Rangno KK. Acute local

reactions after intraarticular hylan for osteoarthritis of the knee.

J Rheumatol. 1995; 22: 1311-1314.

7 Pullman-Mooar S, Mooar P, Sieck M, Clayburne G, & Schumacher HR. Are

there distinctive inflammatory flares after hylan g-f 20 intraarticular

injections? J Rheumatol. 2002; 29: 2611-2614.

8 Chen AL, Desai P, Adler EM, & Di Cesare PE. Granulomatous inflammation

after Hylan G-F 20 viscosupplementation of the knee: a report of six

cases. J Bone Joint Surg Am. 2002; 84-A: 1142-1147.


'/>"/>
SOURCE Ferring Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ferring Announces $10,000 Grand Prize Winner of 2007 My Little Miracle Essay Contest
2. Ferring Pharmaceuticals EUFLEXXA(TM) to Serve as Sponsor for Sprint Force America Masters Track Club
3. Increase in Diagnostic Imaging Fueled by Self-Referring Doctors
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... agency serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing ... fighting to overcome a rare and deadly chromosome abnormality. , After struggling since ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Lori R. ... a member of ElderCounsel, a national organization of elder law and special needs planning ... laws and rules. It also provides a forum to network with elder law attorneys ...
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
Breaking Medicine Technology: